Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT05696080 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

518

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infection

Interventions

BIOLOGICAL: V116
BIOLOGICAL: Placebo
BIOLOGICAL: PCV15
BIOLOGICAL: PPSV23

Sponsor

Merck Sharp & Dohme LLC